Citadel Advisors
HUMA icon

Citadel Advisors’s Humacyte HUMA Stock Holding History

Citadel Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$99.4K Sell
163,900
-86,800
-35% -$90.2K ﹤0.01% 12027
2025
Q4 		$241K Buy
250,700
+73,800
+42% +$105K ﹤0.01% 10637
2025
Q3 		$308K Sell
176,900
-469,600
-73% -$920K ﹤0.01% 10311
2025
Q2 		$1.35M Buy
646,500
+20,800
+3% +$40K ﹤0.01% 6465
2025
Q1 		$1.07M Buy
625,700
+499,800
+397% +$1.88M ﹤0.01% 6820
2024
Q4 		$636K Buy
125,900
+73,900
+142% +$366K ﹤0.01% 8014
2024
Q3 		$283K Buy
52,000
+39,600
+319% +$261K ﹤0.01% 9459
2024
Q2 		$59.5K Sell
12,400
-3,200
-21% -$16.7K ﹤0.01% 11569
2024
Q1 		$48.5K Buy
15,600
+14,100
+940% +$47.4K ﹤0.01% 12199
2023
Q4 		$4.26K Hold
1,500
– – ﹤0.01% 13527
2023
Q3 		$4.39K Buy
1,500
+700
+88% +$2.32K ﹤0.01% 13487
2023
Q2 		$2.29K Buy
+800
New +$2.88K ﹤0.01% 13803
2023
Q1 		– Sell
-12,700
Closed -$26.8K – 15039
2022
Q4 		$26.8K Sell
12,700
-10,800
-46% -$32.8K ﹤0.01% 12877
2022
Q3 		$77K Buy
23,500
+8,500
+57% +$32.6K ﹤0.01% 11305
2022
Q2 		$48K Sell
15,000
-15,900
-51% -$88.4K ﹤0.01% 11961
2022
Q1 		$218K Buy
30,900
+4,200
+16% +$24.5K ﹤0.01% 11315
2021
Q4 		$194K Buy
26,700
+3,900
+17% +$38.6K ﹤0.01% 11889
2021
Q3 		$265K Buy
+22,800
New +$261K ﹤0.01% 11338

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.19B AUM 36.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Citadel Advisors's HUMA Position: Q1 2026 in Review

Citadel Advisors sold out of Humacyte (HUMA) in Q1 2026, closing a stake of 1,566,431 shares — an estimated $1.63M sold.

Citadel Advisors first reported a position in HUMA in Q4 2021 and held it in 16 quarters. The position peaked at $4.96M in Q1 2025. 158 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Citadel Advisors reported no remaining Humacyte position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,566,431 Humacyte shares in Q1 2026, an estimated $1.63M.
  • Citadel Advisors first reported a position in Humacyte in Q4 2021 and held it in 16 quarters.
  • Citadel Advisors's Humacyte position peaked at $4.96M in Q1 2025.
  • 158 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.